Potential Use of Flavopiridol in Treatment of Chronic Diseases
Thejal Srikumar1, Jaya Padmanabhan2,3
1Morsani College of Medicine, University of South Florida, Tampa, Florida, 33612, USA.
Abstract:
This chapter describes the potential use of flavopiridol, a CDK inhibitor with anti-inflammatory and anti-proliferative activities, in the treatment of various chronic diseases. Flavopiridol arrests cell cycle progression in the G1 or G2 phase by inhibiting the kinase activities of CDK1, CDK2, CDK4/6, and CDK7. Additionally, it binds tightly to CDK9, a component of the P-TEFb complex (CDK9/cyclin T), and interferes with RNA polymerase II activation and associated transcription. This in turn inhibits expression of several pro-survival and anti-apoptotic genes, and enhances cytotoxicity in transformed cells or differentiation in growth-arrested cells. Recent studies indicate that flavopiridol elicits anti-inflammatory activity via CDK9 and NFκB-dependent signaling. Overall, these effects of flavopiridol potentiate its ability to overcome aberrant cell cycle activation and/or inflammatory stimuli, which are mediators of various chronic diseases.
Insights
Flavopiridol, a CDK inhibitor, shows potential for treating chronic diseases by halting cell cycle progression and reducing inflammation. Its ability to inhibit specific kinases and transcription factors offers therapeutic promise.
Area of Science:
- Pharmacology
- Molecular Biology
- Chronic Disease Research
Background:
- Chronic diseases are often driven by aberrant cell cycle activation and inflammation.
- Cyclin-dependent kinases (CDKs) play crucial roles in cell cycle regulation.
- Targeting CDKs offers a potential therapeutic strategy for chronic conditions.
Purpose of the Study:
- To explore the therapeutic potential of flavopiridol in treating chronic diseases.
- To elucidate the mechanisms underlying flavopiridol's anti-proliferative and anti-inflammatory effects.
Main Methods:
- Investigating flavopiridol's inhibition of various CDK kinases (CDK1, CDK2, CDK4/6, CDK7, CDK9).
- Analyzing flavopiridol's impact on cell cycle progression (G1/G2 arrest).
- Examining flavopiridol's effects on RNA polymerase II activity and gene transcription.
- Assessing flavopiridol's anti-inflammatory actions via CDK9 and NFκB signaling pathways.
Main Results:
- Flavopiridol inhibits multiple CDKs, leading to cell cycle arrest.
- It interferes with transcription by inhibiting CDK9/cyclin T (P-TEFb complex).
- This results in reduced expression of pro-survival genes and enhanced cytotoxicity or differentiation.
- Flavopiridol demonstrates anti-inflammatory activity through CDK9 and NFκB pathways.
Conclusions:
- Flavopiridol's multifaceted actions, including cell cycle inhibition and anti-inflammatory effects, make it a promising candidate for chronic disease treatment.
- Targeting aberrant cell cycle activation and inflammatory pathways with flavopiridol could overcome key disease mediators.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...